{"prompt": "['4.5.6.4', 'Anti-FVIII Antibodies', 'For the assessment of anti-FVIII antibodies (inhibitors), functional assays that utilize a', 'clotting readout (classic Bethesda or Nijmegen assay) cannot be used for patients on', 'emicizumab therapy as emicizumab drives clotting even in the presence of FVIII inhibitors,', 'causing a false-negative test result (see Section 5.1.3). After the first dose, local', 'measurement of FVIII inhibitors, if indicated, requires use of an ELISA-based test or a', 'chromogenic Bethesda assay.', 'At the discretion of the local investigator, any additional urgent requests to assess FVIII', 'inhibitors will need to be sent to the central laboratory (see Appendix 2', 'Schedule of Biomarker Samples', 'for additional information).', 'Plasma samples for anti-FVIII antibodies will be analysed at the central laboratory.', '4.5.6.5', 'Anti-emicizumab Antibodies', 'Plasma samples are required for immunogenicity assessments to detect anti-emicizumab antibodies.', 'Additional samples to detect anti-emicizumab antibodies may also be drawn at the time of', 'hypersensitivity events or following suspected loss of efficacy. Samples will be analysed at the central', 'laboratory.', '4.5.6.6', 'Pharmacokinetics', 'Plasma samples are required for PK assessments. On days where PK samples are to be collected, the', 'emicizumab injection will be performed in the clinical unit. One single pre-dose sample is required on', 'the applicable visits. Samples will be analysed by the central laboratory.', '4.5.6.7', 'Biomarkers', '4.5.6.7.1', 'Safety Biomarkers', 'Plasma samples for safety biomarker assessment must be citrate plasma. Tests may', 'include, but are not limited to, D-dimer. Samples will be analysed by the central laboratory.', 'See Appendix 2.', '4.5.6.7.2', 'Safety Coagulation System Biomarkers', 'Plasma samples for safety coagulation system biomarker assessment must be citrate', 'plasma. Tests include FVIII:Ag, FIX:Ag and FX:Ag. Samples will be analysed by the central', 'laboratory. See Appendix 2.', '4.5.6.7.3', 'PD Biomarkers', 'Plasma samples for PD biomarker assessment must be citrate plasma. Tests will include,', 'but are not limited to FVIII activity and modified aPTT (one stage). Additional plasma', 'samples will be collected for future exploratory research, which may include tests such as', 'CWA and others (see Appendix 2). Samples will be analysed by the central laboratory.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '32 / Protocol MO39129, Version 3']['4.5.6.7.4', 'Bone and Joint Biomarkers', 'Serum and plasma ethylenediaminetetraacetic acid (EDTA) samples for bone and joint', 'biomarkers must be collected after fasting (no food or drink other than water for at least 8', 'hours prior to the blood draw). Ideally these samples should be collected in the morning', '(before noon), in order to control for diurnal variation. Please consult the Central Laboratory', 'Services Manual for details. The selection of exploratory bone and joint biomarkers to be', 'tested will build on findings from biomarker analyses in other emicizumab trials and may', 'include C-terminal telopeptide of collagen 1 (CTX-1), osteoprotegerin (OPG), procollagen', 'type 1 amino-terminal propeptide (P1NP), and soluble receptor activator of nuclear factor', 'kappa-B ligand (RANK-L) (see Appendix 2', 'Schedule of Biomarker Samples', '). Samples will be analysed by the central laboratory.', 'The following additional study specific plasma samples will be collected and sent to a central', 'laboratory for analysis:', 'Plasma samples for PK analysis', 'Plasma samples for immunogenicity assessments to detect anti emicizumab antibodies', 'Plasma samples for safety biomarker assessments (D dimer)', 'Plasma samples for Fsafetycoagulation system biomarker assessments (FVIII:Ag,', 'FIX:Ag, and FX:Ag)', 'The following biomarker samples will be collected and sent to a central laboratory for', 'analysis (see Appendix 2', 'Schedule of Biomarker Samples', '):', 'Plasma samples for PD biomarker assessments (aPTT and FVIII activity)', 'Plasma and serum samples for bone and joint biomarker assessments.', '4.5.6.8', 'Extra Testing with Use of Bypass Agents', 'In the event of a breakthrough bleed that is treated with bypassing agents, it is', 'recommended that the following laboratory tests will be performed within 24-48 hours of', 'initial bypassing agent use (these tests will be conducted so that the investigator can monitor', 'the patient for potential thromboembolic events and microangiopathic hemolytic anemia or', 'TMA). These tests include: Those tests should ideally be conducted in the central laboratory:', 'Lactate dehydrogenase (LDH)', 'Ideally, samples for these tests should be analysed at the central laboratory. Exceptionally', 'in urgent situations where results are required quickly, local laboratory testing can be used,', 'with results recorded in the eCRF.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '33 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}